Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Mendus AB (publ) banner

Mendus AB (publ)
STO:IMMU

Watchlist Manager
Mendus AB (publ) Logo
Mendus AB (publ)
STO:IMMU
Watchlist
Price: 5.03 SEK -0.59%
Market Cap: kr306.5m
Write Note Create Alert Ask AI

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
kr0
/
kr0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
kr0
/
kr0

Peer Comparison

Country Company Market Cap Operating
Margin
SE
Mendus AB (publ)
STO:IMMU
306.5m SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
386.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
197.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
185.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Other Profitability Ratios

Mendus AB (publ)
Glance View

Market Cap
306.5m SEK
Industry
Biotechnology

Mendus AB is a biomedical company, which engages in the development of cancer immunotherapies. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2013-04-22. The firm develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The firm develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The firm develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.

IMMU Intrinsic Value
10.93 SEK
Undervaluation 54%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

Summary
IMMU intrinsic value, competitors valuation, and company profile.
DCF Valuation
IMMU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
IMMU stock valuation using valuation multiples.
Wall Street Estimates
IMMU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
IMMU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.